Results 61 to 70 of about 1,126 (138)

Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience

Annals of Hematology
Emicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of
Malcolm Su, Sean Yates, Melissa Sanchez, Yu-Min Shen   +3 more
doaj   +1 more source

Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates

Research and Practice in Thrombosis and Haemostasis
Background: Venous thromboembolic events have been reported in persons with hemophilia A who received emicizumab and activated prothrombin complex concentrate (APCC) concomitantly, but the relevant mechanism(s) remains unclear.
Yuto Nakajima, Mitsumasa Osuna, Kuniyoshi Mizumachi, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Keiji Nogami   +6 more
doaj   +1 more source

Benign by design: A paradigm shift in cosmetic ingredient development

International Journal of Cosmetic Science, EarlyView.
Benign by design strategies enable the creation of biodegradable cosmetic ingredients, reducing environmental persistence while maintaining the intended biological activity. This work compiles design rules and tools to guide the development of more sustainable molecules for the cosmetics industry.
Sandra Mota, Klaus Kümmerer, Isabel Martins de Almeida, Emília Sousa   +3 more
wiley   +1 more source

Emicizumab and Acquired Hemophilia A Secondary to Multiple Myeloma.

Acquired hemophilia A (AHA) is a severe bleeding disorder, sometimes linked to plasma cell dyscrasias. In this context, emicizumab, a bispecific antibody, provides stable hemostasis by mimicking factor VIII (FVIII), offering convenience and flexibility ...
Cuschera, Florence, Hermans, Cédric, Vekemans, Marie-Christiane   +2 more
core   +1 more source

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

New England Journal of Medicine, 2017
Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors.We enrolled participants who were 12 years of ...
Johannes, Oldenburg, Johnny N, Mahlangu, Benjamin, Kim, Christophe, Schmitt, Michael U, Callaghan, Guy, Young, Elena, Santagostino, Rebecca, Kruse-Jarres, Claude, Negrier, Craig, Kessler, Nancy, Valente, Elina, Asikanius, Gallia G, Levy, Jerzy, Windyga, Midori, Shima   +14 more
openaire   +6 more sources

Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A

European Journal of Haematology, Volume 117, Issue 5, Page 1292-1300, November 2026.
ABSTRACT Immune tolerance induction (ITI) to eradicate an immune response against factor VIII (FVIII) has been used in hemophilia A (HA) with various success rates, costs, and treatment burden. The present study aimed to identify markers predictive of ITI success.
Marcus Fager Ferrari, Josefin Roslund, Eric Manderstedt, Erik Berntorp, Jan Astermark, Malmö and Hemophilia Inhibitor Genetics Study Investigators   +5 more
wiley   +1 more source

Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention

Research and Practice in Thrombosis and Haemostasis, 2019
Essentials Acquired hemophilia A is a rare bleeding disorder often accompanied by other comorbidities. We describe emicizumab use in acquired hemophilia A complicated by acute coronary syndrome.
Kathryn E. Dane, John P. Lindsley, Michael B. Streiff, Alison R. Moliterno, Mian K. Khalid, Satish Shanbhag   +5 more
doaj   +1 more source

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3

Haemophilia, Volume 32, Issue 5, Page 1264-1271, September/October 2026.
ABSTRACT Introduction Tissue factor pathway inhibitor (TFPI), a key regulator of tissue factor‐initiated coagulation through FXa‐dependent inhibition of the tissue factor‐FVIIa complex, has emerged as a promising target for restoring thrombin generation.
Mankai Ju, Feng Xue, Wei Sun, Fang Li, Ting Xu, Renchi Yang   +5 more
wiley   +1 more source

Optimizing Emergency Department Care for People With Bleeding Disorders: A Scoping Review of Barriers and Interventions for Improvement

Haemophilia, Volume 32, Issue 5, Page 1135-1159, September/October 2026.
ABSTRACT Background Emergency department (ED) care is critical for managing acute bleeding events in people with bleeding disorders. Despite international guidelines recommending haemostatic treatment within 30–60 min, delays and deviations from best practices are common and associated with poorer outcomes.
Ling‐Yi Guo, Diane L. Lorenzetti, Natalia Rydz, Dawn Goodyear, Julia Hews‐Girard, Garrick Mok, Roy Khalife, Kelsey Uminski   +7 more
wiley   +1 more source

Physical Activity, Bleeding Incidence and Health‐Related Quality of Life, in Patients With Haemophilia A Without Inhibitors, Treated With Emicizumab: A Post‐Hoc Descriptive Analysis of the Power Study Data

Haemophilia, EarlyView.
Matteo Nicola Dario Di Minno, Berardino Pollio, Ezio Zanon, Gaetano Giuffrida, Sara Bendinelli, Raffaella Perrone, Giancarlo Castaman, the POWER study sites group   +7 more
wiley   +1 more source